Loading...
XJPX4592
Market cap314mUSD
Jan 21, Last price  
691.00JPY
1D
0.00%
1Q
-32.59%
Jan 2017
-46.31%
IPO
-62.05%
Name

SanBio Co Ltd

Chart & Performance

D1W1MN
XJPX:4592 chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.12%
Rev. gr., 5y
-17.56%
Revenues
0k
204,286,0003,229,211,0001,174,644,000949,543,000490,509,000741,614,000447,226,0000000
Net income
-2.64b
L-52.44%
-589,454,0001,736,265,000-988,397,000-1,835,296,000-3,940,327,000-2,920,563,000-5,157,716,000-3,385,875,000-4,677,856,000-5,559,584,000-2,644,000,000
CFO
-4.78b
L-35.72%
-111,534,000-218,504,000-1,362,083,000-1,796,175,000-1,906,769,000-3,968,342,000-5,717,292,000-5,215,683,000-6,546,664,000-7,434,147,000-4,778,453,000
Earnings
Mar 17, 2025

Profile

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
URL
https://www.sanbio.jp/
IPO date
Apr 08, 2015
Employees
65
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑012023‑012022‑012021‑012020‑012019‑012018‑012017‑012016‑012015‑01
Income
Revenues
Cost of revenue
2,863,504
7,923,923
6,753,350
Unusual Expense (Income)
NOPBT
(2,863,504)
(7,923,923)
(6,753,350)
NOPBT Margin
Operating Taxes
102,000
862,141
117,433
Tax Rate
NOPAT
(2,965,504)
(8,786,064)
(6,870,783)
Net income
(2,644,000)
-52.44%
(5,559,584)
18.85%
(4,677,856)
38.16%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,651,366
10,956,657
3,749
BB yield
-7.17%
-25.43%
-0.01%
Debt
Debt current
268,000
268,000
512,500
Long-term debt
397,000
665,000
2,012,500
Deferred revenue
Other long-term liabilities
(1)
1,000
Net debt
(3,789,716)
(5,799,803)
(2,032,040)
Cash flow
Cash from operating activities
(4,778,453)
(7,434,147)
(6,546,664)
CAPEX
(11,078)
(8,003)
(56,077)
Cash from investing activities
(19,028)
(10,100)
(66,261)
Cash from financing activities
2,383,331
9,445,783
(1,495,484)
FCF
(2,961,961)
(8,775,179)
(6,787,747)
Balance
Cash
4,454,716
6,732,775
4,557,006
Long term investments
28
34
Excess cash
4,454,716
6,732,803
4,557,040
Stockholders' equity
(4,234,615)
(1,769,868)
(4,982,234)
Invested Capital
7,692,014
7,131,173
9,419,875
ROIC
ROCE
EV
Common stock shares outstanding
65,323
57,918
51,789
Price
566.00
-23.92%
744.00
-31.30%
1,083.00
-33.84%
Market cap
36,972,621
-14.20%
43,091,116
-23.17%
56,087,634
-33.84%
EV
33,182,905
41,210,269
54,823,950
EBITDA
(2,849,000)
(7,899,308)
(6,620,883)
EV/EBITDA
Interest
25,813
25,270
44,606
Interest/NOPBT